European Cancer Organisation
login

EACR24 Call for Abstracts

Abstract Submission is now closed.

The Scientific Committee will make the selection of abstracts for oral and poster presentations by early April.  The presenting author will receive an e-mail with the result of the review and the Scientific Committee’s decision on the abstract.

Presenting authors will be entitled to register at the extended early registration rate until 10 days after abstract notifications have been sent to them.

 

Abstract Regulations

With the submission of an abstract to EACR24, the first author (presenting author):

  • Accepts responsibility for the accuracy of the submitted abstract.
  • Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
  • Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
  • States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
  • Gives permission for the abstract, when selected for presentation (oral or poster), to be published.  Submitted abstracts cannot be withdrawn after 6 May 2016.

 

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

  • The abstract must be submitted in good English.  The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
  • Abstract titles should be brief and should reflect the content of the abstract.
  • Commercial names may not be used in the abstract title.
  • No more than 10 authors can be listed.  Only institutional affiliations, cities and countries should follow.
  • Abstracts should be organised under the headings:
    • Introduction
    • Material and method
    • Results and discussion
    • Conclusion
  • The online abstract submission procedure will not accept abstracts that exceed 2,900 characters (body of the abstract)
  • Abbreviations may be used if standard or if spelled out and defined at the first use.  Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
  • Supplementary data or appendices will not be accepted.
  • Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by e-mail from the
EACR24 Congress Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process, please contact: 
Rebekka Mattyasovszky
E-mail: rebekka.mattyasovszky@ecco-org.eu

 

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and poster presentations by early April.  The presenting author will receive an e-mail with the result of the review and the Scientific Committee’s decision on the abstract.

If a selected author cannot attend, the presenting author should assign a replacement.

The following presentation formats are applicable for EACR24:

  1. Oral presentation: the abstract is selected for oral presentation in a main programme symposium
  2. Poster: abstracts that have been selected for presentation in poster format.  Posters are grouped by topic and will be displayed during specific Poster Sessions. A formal Poster Defence Session will be scheduled.

Please note that if the abstract is accepted for oral or poster presentation, the abstract will only be published in the Proceedings Book if one of the authors is a registered participant and full payment has been received by the advised deadline.

 

Abstract Presenter Registration

Presenting authors will be entitled to register at the extended early registration rate until 10 days after abstract notifications have been sent to them.

 

Abstract Submission

Abstract submission procedure
Abstracts must be submitted on-line, from 01 December 2015 to 02 March 2016, via the ECCO website.

Please follow the instructions on the screen.

Please note:

  • When finished with the online submission, please click the “FINAL SUBMISSION” button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
  • If you need to edit your abstract at a later stage please click “SAVE AND CLOSE”. This button allows you to update your abstract before final submission.
  • After clicking “SAVE AND CLOSE”, your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click “FINAL SUBMISSION”. If you have not FINAL SUBMITTED your abstract by the deadline of 02 March 2016 your abstract can not be accepted.
  • Within 24 hours of submission, only the presenting author will receive a confirmation by e-mail.  This confirmation of abstract submission does not mean your abstract has been selected for presentation.
  • If you do not receive any confirmation, please contact Rebekka Mattyasovszky (rebekka.mattyasovszky@ecco-org.eu) within one week following the submission of the abstract.
  • Submitting an abstract for EACR24 does not constitute registration for the congress. Abstract presenters must register to attend EACR24 by following the instructions for registration on the website.

For questions regarding the on-line submission process, please contact: rebekka.mattyasovszky@ecco-org.eu

Only abstracts submitted online can be accepted.  Abstracts submitted on paper or as e-mail attachment will not be considered.

 

Topics for Abstract Submission 

1. CELL AND TUMOUR BIOLOGY

  • Cell Proliferation/cell cycle
  • Cell Death / Autophagy
  • Oncogenes and Tumour Suppressor Genes
  • Tumour Progression: Invasion and Metastasis
  • Metastases and EMT
  • Tumour Microenvironment
  • Tumour Angiogenesis
  • Tumour Immunology AND Inflammation
  • Aging and Cancer
  • Senescence
  • Cancer Cell Metabolism
  • Cancer Initiating Cells / Cancer Stem Cells
  • Tumour heterogeneity

2. CANCER GENOMICS, EPIGENETICS and GENOMIC INSTABILITY

  • Genomic Alterations in Cancer
  • Functional  Genomics
  • Epigenetic mechanisms and RNA
  • Genetic instability
  • Deep sequencing

3. SIGNALING PATHWAYS

  • Receptors and Signal Transduction
  • Gene Expression, Transcriptional Regulation
  • Systems biology
  • Computational models of biological systems
  • Omics technologies

4. CARCINOGENESIS

  • Mutagenesis, Carcinogen Metabolism
  • Promotion and Progression
  • DNA Damage and Repair
  • Viral Oncogenesis

5. TRANSLATIONAL RESEARCH

  • Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
  • Molecular pathology
  • Biomarkers with clinical relevance, imaging
  • Prognostic biomarkers of therapy response
  • Prognostic value of oncogenomics
  • Clinical Phase I/II trials with targeted drugs and novel agents
  • Bioinformatics in therapies and clinical trials
  • Animal models of cancer
  • Infrastructures (biobanks, databases, genomic resources, others)

6. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS

  • Drug Discovery / Drug Design
  • Novel Targets, Delivery Systems
  • Mechanisms of Drug Action, Drug Profiling
  • Drug Resistance
  • Novel Approaches to Diagnosis of Cancer
  • New Therapies
  • Companion diagnostics
  • Personalised medicine

7. TUMOUR IMMUNOLOGY

  • Tumour Immunology
  • Immune Suppression and Escape
  • Tumour antigens and immune effectors
  • Immunotherapy and Cancer Vaccines

8. RADIOBIOLOGY / RADIATION ONCOLOGY

  • Tumour Cell Sensitisation to Radiotherapy
  • Radiation-activated Signaling Pathways
  • Cell Cycle and Apoptosis in Radiation  Responses
  • Radiation Oncology; Preclinical and Clinical
  • Translational radiation research

9. MOLECULAR AND GENETIC EPIDEMIOLOGY

  • Risk Factors
  • Biomarkers
  • Risk Assessment
  • Susceptibility Genes
  • Genotype / Phenotype Correlations
  • Genetic Polymorphisms and Cancer Susceptibility
  • Epidemiology

10. PREVENTION and EARLY DETECTION

  • Preclinical Prevention Studies, Markers and Prevention
  • Clinical Prevention Studies
  • Vaccination Against Cancer

11. OTHER

If you indicate “preference for Oral presentation” you will also have to mark which of the below mentioned Symposia is best suited for your abstract:

     1. BREAKTHROUGH CANCER MODELS
     2. BREAKTHROUGH TOOLS IN CANCER GENETICS
     3. CANCER IMMUNOLOGY
     4. DIAGNOSING CANCER EARLIER
     5. DNA DAMAGE
     6. EPIGENETICS
     7. INFLAMMATION AND CANCER
     8. INVASION AND METASTASIS
     9. LIQUID BIOPSIES IN CANCER
    10. MECHANISMS OF DRUG RESISTANCE
    11. NOVEL TARGETED THERAPIES
    12. SENESCENCE AND AGING
    13. STEM CELLS
    14. THE TUMOUR MICROENVIRONMENT
    15. TUMOUR HETEROGENEITY AND EVOLUTION
    16. TUMOUR METABOLISM
    17. TUMOUR SUPPRESSORS

 

Download the Call for Abstracts in PDF.

 

PRINT THIS PAGE Page last modified: